Mitral valve annuloplasty

Affluent Medical : 2023 financial results and update on clinical activities under development.

Retrieved on: 
星期五, 五月 3, 2024
Medtech, FDA, Risk, De novo, Death, Mitral regurgitation, Doctor of Philosophy, Wound healing, Mitral valve annuloplasty, Boston Scientific, Ticker, Wealth, Urinary incontinence, Woman, Christophe, Food, Neurostimulation, Myocardial infarction, Aix-en-Provence, DSM-IV codes, LCEA, Mitral valve, TAVI, Minerva, Certification, Heart, Quality assurance, System, Anatomy, Exercise, NYHA, Dry, Marketing, Clinical trial, American College, Development director, MD, Endocarditis, Medtronic, Patient, Tricuspid valve, Acquisition, Medical device

Affluent Medical : 2023 financial results and update on clinical activities under development.

Key Points: 
  • Affluent Medical : 2023 financial results and update on clinical activities under development.
  • Affluent Medical estimates that KaliosTM would avoid repeat surgery for 30-40% of patients within five years of their operation.
  • In September 2023, the Company presented interim data on 20 patients treated in five clinical centers in Europe after one year of implantation.
  • In July 2023, Affluent Medical announced the appointments of Christophe de Vregille as Chief Financial Officer and Benjamin Renault as Development Director.

Global Tricuspid Valve Repair Market to Reach $1 Billion by 2030, Driven by Rising Cardiovascular Disease Incidence and Technological Advancements - ResearchAndMarkets.com

Retrieved on: 
星期三, 七月 26, 2023
Health, Surgery, Cardiology, Other Health, CVD, Myxoma, Wilford Hall Ambulatory Surgical Center, Prevalence, Ebstein's anomaly, COVID-19, Cardiovascular disease, Fatality, Ageing, Carcinoid, Research, USD, Mitral valve, Incidence, GDP, Growth, Genetically modified bacteria, WHO, Pulmonary hypertension, Death, Mitral valve annuloplasty, Tricuspid valve, Pharmaceutical industry, Hospital, Tricuspid valve stenosis

The "Tricuspid Valve Repair Market Size, Share & Trends Analysis Report By End-use (Ambulatory Surgical Centers, Hospitals), By Indication (Tricuspid Valve Regurgitation, Tricuspid Valve Stenosis), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tricuspid Valve Repair Market Size, Share & Trends Analysis Report By End-use (Ambulatory Surgical Centers, Hospitals), By Indication (Tricuspid Valve Regurgitation, Tricuspid Valve Stenosis), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global tricuspid valve repair market size is expected to reach USD 1.0 billion by 2030.
  • The main causes of tricuspid are bacterial infection, Ebstein's anomaly, connective tissue problems, carcinoid tumors, myxomatous degeneration, and other cardiac disorders or ailments, which cause pulmonary hypertension.
  • Annuloplasty rings are placed during tricuspid valve repair surgeries to improve long-term outcomes.

Cardiac Implants Announces Successful Therapeutic Adjustment Procedure Using Tri-Ring™ Percutaneous Annuloplasty Device

Retrieved on: 
星期三, 九月 14, 2022
Health, Medical Devices, Other Health, Other Science, General Health, Science, Cardiology, Mitral valve, Hospital, NewYork-Presbyterian Hospital, Prevalence, LLC, Tricuspid valve, Tri, Population, Implant, Patient, Weill Cornell Medicine, Heart, CEO, Mitral valve annuloplasty, CA, TR, Area studies, Weill Cornell Medical Center, Medicine, Neck, TCT, Carrie, Medical device

Cardiac Implants LLC has announced the successful initial deployment of its Annuloplasty ring with implementation of a therapeutic adjustment procedure using its innovative Tri-Ring percutaneous annuloplasty device.

Key Points: 
  • Cardiac Implants LLC has announced the successful initial deployment of its Annuloplasty ring with implementation of a therapeutic adjustment procedure using its innovative Tri-Ring percutaneous annuloplasty device.
  • The adjustment procedure represents the first minimally invasive percutaneous annuloplasty in the United States using a two-stage clinical approach and utilized Cardiac Implants second-generation Tri-Ring percutaneous annuloplasty device , a complete circular ring implanted from the internal jugular vein in the neck.
  • We are very excited to see the potential for the performance of the Tri-Ring Annuloplasty Device, said Dr. Mark Turco, CEO, Cardiac Implants.
  • The Cardiac Implants annuloplasty device allows structural heart interventionalists to percutaneously deliver a complete ring on the tricuspid valve annulus.

FDA Grants Micro Interventional Devices, Inc. Breakthrough Device Designation for the MIA™-T Percutaneous Tricuspid Annuloplasty System

Retrieved on: 
星期四, 五月 27, 2021
Medical specialties, Clinical medicine, Medicine, Heart valves, Cardiac surgery, Valvular heart disease, Cardiology, Tricuspid insufficiency, Mitral valve annuloplasty, TR, Tricuspid valve, Regurgitation

NEWTOWN, Pa., May 27, 2021 /PRNewswire/ -- Micro Interventional Devices (MID) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its MIA-T Percutaneous Tricuspid Annuloplasty System.

Key Points: 
  • NEWTOWN, Pa., May 27, 2021 /PRNewswire/ -- Micro Interventional Devices (MID) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its MIA-T Percutaneous Tricuspid Annuloplasty System.
  • The MIA-T system treats moderate-severe tricuspid regurgitation (TR) via a 12F catheter-based system.
  • The safety and performance of MIA-T has been demonstrated in the STTAR, Study of Transcatheter Tricuspid Annular Repair, conducted at 6 European clinical sites.
  • * We expect that breakthrough device designation will speed the process to commercialization so patients, physicians and the healthcare system can benefit from this technology."

FDA Grants Micro Interventional Devices, Inc. Breakthrough Device Designation for the MIA™-T Percutaneous Tricuspid Annuloplasty System

Retrieved on: 
星期四, 五月 27, 2021
Medical specialties, Clinical medicine, Medicine, Heart valves, Cardiac surgery, Valvular heart disease, Cardiology, Tricuspid insufficiency, Mitral valve annuloplasty, TR, Tricuspid valve, Regurgitation

NEWTOWN, Pa., May 27, 2021 /PRNewswire/ -- Micro Interventional Devices (MID) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its MIA-T Percutaneous Tricuspid Annuloplasty System.

Key Points: 
  • NEWTOWN, Pa., May 27, 2021 /PRNewswire/ -- Micro Interventional Devices (MID) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its MIA-T Percutaneous Tricuspid Annuloplasty System.
  • The MIA-T system treats moderate-severe tricuspid regurgitation (TR) via a 12F catheter-based system.
  • The safety and performance of MIA-T has been demonstrated in the STTAR, Study of Transcatheter Tricuspid Annular Repair, conducted at 6 European clinical sites.
  • * We expect that breakthrough device designation will speed the process to commercialization so patients, physicians and the healthcare system can benefit from this technology."

Global Annuloplasty Rings Market 2021-2025: Focus on the Development of Personalized Annuloplasty Rings and the Development of Biodegradable Annuloplasty Rings - ResearchAndMarkets.com

Retrieved on: 
星期五, 五月 21, 2021
Medical devices, Health, Cardiac surgery, Medical specialties, Anatomy, Heart, Mitral valve annuloplasty, Mitral valve, Heart valve

b'The "Global Annuloplasty Rings Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe annuloplasty rings market is poised to grow by $28.83 million during 2021-2025, progressing at a CAGR of over 3%\nThe market is driven by the increasing prevalence of heart valve diseases, increasing preference for mitral valve repair over mitral valve replacement, and technological advances.\nThe report on the annuloplasty rings market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Key Points: 
  • b'The "Global Annuloplasty Rings Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe annuloplasty rings market is poised to grow by $28.83 million during 2021-2025, progressing at a CAGR of over 3%\nThe market is driven by the increasing prevalence of heart valve diseases, increasing preference for mitral valve repair over mitral valve replacement, and technological advances.\nThe report on the annuloplasty rings market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
  • This is to help companies strategize and leverage all forthcoming growth opportunities.\nThe study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
  • The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.\n'

BioStable Science & Engineering Announces CE Mark Approval for the HAART 200 Aortic Annuloplasty Device & Surpasses 1,000 Patients Treated Worldwide with the HAART Devices

Retrieved on: 
星期三, 四月 21, 2021
Biotechnology, Surgery, Medical devices, Health, Cardiology, Cardiac surgery, Medical specialties, Clinical medicine, Medicine, Aortic valve repair, Aortic valve replacement, Bicuspid aortic valve, Aortic valve, Aortic insufficiency, Mitral valve annuloplasty, BAV, Valve replacement

b'BioStable Science & Engineering, Inc. (\xe2\x80\x9cBioStable\xe2\x80\x9d) announced today the company has received CE Mark approval for the HAART 200 Aortic Annuloplasty Device for use during bicuspid aortic valve repair.

Key Points: 
  • b'BioStable Science & Engineering, Inc. (\xe2\x80\x9cBioStable\xe2\x80\x9d) announced today the company has received CE Mark approval for the HAART 200 Aortic Annuloplasty Device for use during bicuspid aortic valve repair.
  • With CE Mark approval of both the HAART 300 and HAART 200 Aortic Annuloplasty Devices, BioStable will be able to offer surgeons within the European Union a comprehensive portfolio of aortic valve repair solutions that address all forms of aortic valve insufficiency.
  • Approximately 53% of BAV patients require aortic valve surgery within 25 years of being diagnosed [1].
  • Most BAV patients undergo aortic valve replacement between 40 and 60 years of age, subjecting them to increased risk of reoperation or complications associated with valve replacement technologies [2].

Global and China Annuloplasty Rings Markets, 2016-2021 & 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
星期四, 三月 11, 2021
Medical devices, Health, Cardiac surgery, Mitral valve annuloplasty, Economy of China, Market research

The "Global and Chinese Annuloplasty Rings Industry, 2021 Market Research Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global and Chinese Annuloplasty Rings Industry, 2021 Market Research Report" report has been added to ResearchAndMarkets.com's offering.
  • The 'Global and Chinese Annuloplasty rings Industry, 2021 Market Research Report' is a professional and in-depth study on the current state of the global Annuloplasty rings industry with a focus on the Chinese market.
  • Through statistical analysis, the report depicts the global and Chinese total market of Annuloplasty rings industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.
  • Overall, the report provides an in-depth insight of the 2021 global and Chinese Annuloplasty rings industry covering all important parameters.

Valcare Medical Announces First-in-Human Transseptal Implant of the AMEND™ Annuloplasty Ring for Mitral Valve Repair

Retrieved on: 
星期三, 一月 27, 2021
Cardiac surgery, Medical specialties, Medicine, Clinical medicine, Mitral valve annuloplasty, Mitral valve, Heart valve, Regurgitation, John G. Webb, MitraClip

HERZLIYA, Israel, Jan. 27, 2021 /PRNewswire/ -- Valcare Medical Ltd. developer of transcatheter mitral and tricuspid valve repair and replacement solutions, announces that it has successfully completed its first-in-human transseptal delivery of the AMENDannuloplasty ring.

Key Points: 
  • HERZLIYA, Israel, Jan. 27, 2021 /PRNewswire/ -- Valcare Medical Ltd. developer of transcatheter mitral and tricuspid valve repair and replacement solutions, announces that it has successfully completed its first-in-human transseptal delivery of the AMENDannuloplasty ring.
  • Valcare's AMEND mitral valve repair device is an innovative, clinically proven, D-shaped, semi-rigid closed ring with unique anchoring capabilities.
  • Following demonstration of safety and efficacy of the AMEND ring in transapical procedures, we are now delivering this D-shaped annuloplasty ring via a transseptal approach.
  • Valcare Medical is a privately held medical device company, dedicated to providing innovative transcatheter technologies for the treatment of mitral and tricuspid regurgitation.

Valcare Medical Announces First-in-Human Transseptal Implant of the AMEND™ Annuloplasty Ring for Mitral Valve Repair

Retrieved on: 
星期三, 一月 27, 2021
Cardiac surgery, Medical specialties, Medicine, Clinical medicine, Mitral valve annuloplasty, Mitral valve, Heart valve, Regurgitation, John G. Webb, MitraClip

HERZLIYA, Israel, Jan. 27, 2021 /PRNewswire/ -- Valcare Medical Ltd. developer of transcatheter mitral and tricuspid valve repair and replacement solutions, announces that it has successfully completed its first-in-human transseptal delivery of the AMENDannuloplasty ring.

Key Points: 
  • HERZLIYA, Israel, Jan. 27, 2021 /PRNewswire/ -- Valcare Medical Ltd. developer of transcatheter mitral and tricuspid valve repair and replacement solutions, announces that it has successfully completed its first-in-human transseptal delivery of the AMENDannuloplasty ring.
  • Valcare's AMEND mitral valve repair device is an innovative, clinically proven, D-shaped, semi-rigid closed ring with unique anchoring capabilities.
  • Following demonstration of safety and efficacy of the AMEND ring in transapical procedures, we are now delivering this D-shaped annuloplasty ring via a transseptal approach.
  • Valcare Medical is a privately held medical device company, dedicated to providing innovative transcatheter technologies for the treatment of mitral and tricuspid regurgitation.